Columbia Asset Management Cuts Stock Position in Abbott Laboratories $ABT

Columbia Asset Management lessened its holdings in Abbott Laboratories (NYSE:ABT) by 2.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,041 shares of the healthcare product maker’s stock after selling 125 shares during the period. Columbia Asset Management’s holdings in Abbott Laboratories were worth $686,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Generali Investments CEE investicni spolecnost a.s. raised its stake in shares of Abbott Laboratories by 2.9% in the 2nd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 28,058 shares of the healthcare product maker’s stock valued at $3,816,000 after acquiring an additional 800 shares during the period. Liberty Capital Management Inc. raised its stake in shares of Abbott Laboratories by 5.5% in the 2nd quarter. Liberty Capital Management Inc. now owns 46,340 shares of the healthcare product maker’s stock valued at $6,303,000 after acquiring an additional 2,399 shares during the period. Cooper Financial Group raised its stake in shares of Abbott Laboratories by 3.4% in the 2nd quarter. Cooper Financial Group now owns 5,604 shares of the healthcare product maker’s stock valued at $762,000 after acquiring an additional 184 shares during the period. PGGM Investments increased its stake in Abbott Laboratories by 28.0% during the 2nd quarter. PGGM Investments now owns 844,272 shares of the healthcare product maker’s stock worth $114,829,000 after buying an additional 184,602 shares during the period. Finally, BCU Wealth Advisors LLC increased its stake in Abbott Laboratories by 3.9% during the 2nd quarter. BCU Wealth Advisors LLC now owns 4,698 shares of the healthcare product maker’s stock worth $639,000 after buying an additional 177 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.6%

NYSE ABT opened at $133.97 on Wednesday. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company has a 50-day simple moving average of $131.48 and a 200-day simple moving average of $131.22. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a market capitalization of $233.17 billion, a PE ratio of 16.79, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. Abbott Laboratories’s revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is presently 29.57%.

Analysts Set New Price Targets

Several research firms recently issued reports on ABT. Royal Bank Of Canada lifted their price target on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and lifted their price target for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Mizuho lifted their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Finally, BTIG Research dropped their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $145.22.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.